Pathologically Confirmed Cancer Refractory to Conventional Therapy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Pathologically Confirmed Cancer Refractory to Conventional Therapy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (2 shown)

CompletedPhase 1

NCT05990920

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conve…

The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy. The main quest…

United States6 participantsStarted 2023-08-23

Treatment: SNK02

CompletedPhase 1

NCT03941262

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Convention…

The purpose of the study is to evaluate the safety and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent and in combination with…

United States27 participantsStarted 2019-07-15

Treatment: SNK01, Avelumab